Lexicon to Present at Digestive Disease Week

THE WOODLANDS, Texas -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will be giving presentations on two of its clinical-stage drug development programs at the Digestive Disease Week (DDW) conference in Chicago, Illinois on Sunday, May 31, and Monday, June 1. DDW is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Lexicon give presentations on LX1031, an oral drug candidate for the treatment of irritable bowel syndrome (IBS), and LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1031 is currently in a Phase 2 clinical trial in patients with non-constipating IBS, and LX1032 is entering a Phase 2 study in patients with carcinoid syndrome.

Both presentations will be available online at the company's Web site after June 1.